



Market Announcement

19 August 2020

MGC Pharmaceuticals (ASX: MXC) – Trading Halt

Description

The securities of MGC Pharmaceuticals ('MXC') will be placed in trading halt at the request of MXC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 21 August 2020 or when the announcement is released to the market.

Issued by

Jessica Coupe

Adviser, Listings Compliance (Perth)

19 August 2020

Australian Securities Exchange
Level 40, Central Park
152-158 St Georges Tce
Perth WA 6000

Via email: tradinghaltspert@asx.com.au

Dear Sir/Madam

The Directors of MGC Pharmaceuticals Ltd (the “Company”) request that the Company’s securities be placed in a voluntary trading halt immediately in accordance with ASX Listing Rule 17.1, pending the release of an announcement by the Company in relation to interim results on the ArtemiC Phase II clinical trial.

The Company requests that the trading halt end on the earlier of the commencement of normal trading on Friday 21 August 2020, or when the announcement referred to above is released to the market.

The Company is not aware of any reason why the trading halt should not be granted, nor of any other information necessary to inform the market about the trading halt, and the Company confirms that the request for a trading halt is material.

Yours faithfully

[sent electronically without signature]

Rachel Kerr
Company Secretary